新冠疫苗额外剂次安全性监测:美国2021年8-9月
美国CDC利用v-safe主动监测系统,分析2021年8月12日至9月19日22,191名报告接种新冠疫苗额外剂次者的健康调查数据。在完成三剂健康调查的12,591人中,第三剂后局部和全身反应报告率分别为79.4%和74.1%,与第二剂后(77.6%和76.5%)相近,未发现异常反应模式,多为轻中度。
要点
- 新冠疫苗额外剂次后局部和全身反应报告率与第二剂相近。
- 绝大多数(97.6%)报告者完成基础两剂mRNA疫苗后接种同款第三剂。
- 初始监测未发现额外剂次后非预期的不良反应模式。
核心结论
- 新冠疫苗额外剂次接种后未发现非预期的不良反应模式,多数不良反应为轻中度。
研究设计与样本
- 基于v-safe自愿性智能手机安全监测系统的描述性分析,分析2021年8月12日至9月19日报告接种额外剂次的22,191名注册者数据。
主要发现
- 22,191名v-safe注册者报告接种新冠疫苗额外剂次,其中97.6%报告完成基础两剂mRNA疫苗后接种同款第三剂。
- 在完成全部三剂健康调查的12,591人(58.1%)中,第三剂后局部反应报告率为79.4%,全身反应为74.1%。
- 第二剂后局部和全身反应报告率分别为77.6%和76.5%,与第三剂后相近。
关键数值与推荐
- 2021年8月12日FDA修订EUA,授权中重度免疫受损者在完成基础免疫后接种额外剂次。
- 2021年9月22日FDA授权≥65岁、重症高风险或职业/机构暴露高风险者在完成基础系列≥6个月后接种额外剂次。
临床怎么用
- 监测数据可为新冠疫苗额外剂次的推荐提供安全性依据,支持继续监测。
局限性
- v-safe为自愿报告系统,可能存在报告偏倚,且健康调查完成率有限(58.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize administration of an additional dose after completion of a primary vaccination series to eligible persons with moderate to severe immunocompromising conditions (1,2). On September 22, 2021, FDA authorized an additional dose of Pfizer-BioNTech vaccine ≥6 months after completion of the primary series among persons aged ≥65 years, at high risk for severe COVID-19, or whose occupational or institutional exposure puts them at high risk for COVID-19 (1). Results from a phase 3 clinical trial conducted by Pfizer-BioNTech that included 306 persons aged 18-55 years showed that adverse reactions after receipt of a third dose administered 5-8 months after completion of a 2-dose primary mRNA vaccination series were similar to those reported after receipt of dose 2; these adverse reactions included mild to moderate injection site and systemic reactions (3). CDC developed v-safe, a voluntary, smartphone-based safety surveillance system, to provide information on adverse reactions after COVID-19 vaccination. Coincident with authorization of an additional dose for persons with immunocompromising conditions, the v-safe platform was updated to allow registrants to enter information about additional doses of COVID-19 vaccine received. During August 12-September 19, 2021, a total of 22,191 v-safe registrants reported receipt of an additional dose of COVID-19 vaccine. Most (97.6%) reported a primary 2-dose mRNA vaccination series followed by a third dose of the same vaccine. Among those who completed a health check-in survey for all 3 doses (12,591; 58.1%), 79.4% and 74.1% reported local or systemic reactions, respectively, after dose 3, compared with 77.6% and 76.5% who reported local or systemic reactions, respectively, after dose 2. These initial findings indicate no unexpected patterns of adverse reactions after an additional dose of COVID-19 vaccine; most of these adverse reactions were mild or moderate. CDC will continue to monitor vaccine safety, including the safety of additional doses of COVID-19 vaccine, and provide data to guide vaccine recommendations and protect public health.
引用
- Hause AM, Baggs J, Gee J, et al. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34591835. doi:10.15585/mmwr.mm7039e4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。